On July 21, 2021, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for pembrolizumab, marketed as Keytruda. This regulatory action, identified as BLA 125514 S-105, was based on new efficacy data, signifying an expansion of the drug's approved therapeutic applications.
What this means
This supplemental FDA approval for pembrolizumab (Keytruda) indicates that the U.S. Food and Drug Administration has reviewed and accepted additional clinical evidence demonstrating the drug's effectiveness. Supplemental applications, such as BLA 125514 S-105, are typically submitted by manufacturers to expand a drug's existing label, allowing for its use in new indications, different patient populations, or under modified dosing regimens. The classification of this approval as "efficacy" confirms that the decision was based on demonstrated clinical benefit. For healthcare professionals, this means an expanded scope for prescribing Keytruda, potentially offering new treatment options for patients within the context of the newly approved use. Researchers and patient advocates will be interested in the specific details of this label expansion, which would outline the precise conditions or populations for which Keytruda's efficacy has now been validated.
Source
The information regarding this supplemental approval for Keytruda (pembrolizumab) was obtained from the U.S. Food and Drug Administration (FDA). The approval, identified as BLA 125514 S-105, was recorded on July 21, 2021, and is publicly accessible on the FDA's official website, accessdata.fda.gov.